J&J MedTech Falls Short In Q3 As Middle East, China And Abiomed Weigh On Growth
International weakness and an Abiomed slump weigh on the segment, while executives promise a better fourth quarter.
Medtech Insight - October 13, 2026

Ex-FDA Chief Woodcock: Spinal Cord Injury Drugs Need Different Trials
Spinal cord injury needs rare-disease-style flexibility, said Janet Woodcock in an interview. Randomized trials require prespecified, individualized responder indices and within-patient controls, not single or composite endpoints.
In Vivo - October 13, 2026

Roche Adds To Muscle-Sparing Efforts In Obesity With Rona Deal
Deal Snapshot: After giving up on emugrobart as a lean mass-sparing agent for obesity, Roche brings in an ALK7 RNAi therapy from Rona, its second licensing deal for a muscle-sparing candidate in recent months.
Scrip - October 13, 2026

EU Approves Kimberly-Clark’s Acquisition Of Kenvue After Divestments Agreed
The European Commission cleared Kimberly-Clark’s $48.7bn Kenvue buyout on condition it sells its EEA tampon and feminine hygiene brands, including Kotex. The remedy follows similar feminine care divestments in Australia and Brazil.
HBW Insight - October 13, 2026

Stock Watch: Foghorn And Sanofi Get The Market’s Verdict
Foghorn Therapeutics’s market cap fell below its cash following Eli Lilly’s exit and Sanofi hit a multi-year low after expanding its alliance with Regeneron. When pipeline misses accumulate, share price reactions say a good deal about how investors value what is left.
Scrip - October 13, 2026

Ascend Laboratories And Mayne Pharma Settle For $1m Over Generic Price-Fixing
A further settlement of over $1m has been secured to compensate victims of an alleged US generic pricing inflation scheme through which companies were accused of illegally colluding to raise prices.
Generics Bulletin - October 13, 2026

Bambusa And Aspen Join Biotech’s IPO Queue
This year’s resurgence in IPOs continues, but there are signs that investor enthusiasm for biotech has cooled in recent weeks.
Scrip - October 13, 2026

Agilent’s $240m Proscia Deal Brings Software To A Hardware-Heavy Pathology Portfolio
Proscia built its business by working with everyone's equipment. Its new owner sells some of that equipment. The $240m deal hands Agilent a software layer for its tissue-diagnostics stack, along with a question about how open that layer can stay.
Medtech Insight - October 13, 2026

Immuto Reads Hidden Disease Architecture, Daiichi Makes Oncology Bet
Immuto Scientific is using its AI-driven platform to unlock novel antibody targets hidden in the protein conformations of living cancer cells while a Daiichi Sankyo option-and-license deal is in the bag, Co-Founder Daniel Benjamin tells Scrip in this interview.
Scrip - October 13, 2026

Novo’s Semaglutide Patent Iceberg Keeps Shrinking In Europe
After a semaglutide cardiovascular patent that ran to 2037 was invalidated by the EPO, Novo told Generics Bulletin that no significant business impact is expected. At the same time, the originator is being challenged by Sandoz at the UPC over an improved dosage regimen patent.
Generics Bulletin - October 13, 2026

Formycon Breaks New Ground In More Ways Than One With US Keytruda Biosimilar Filing
Formycon has claimed the first Keytruda biosimilar filing with the US FDA, with the Zydus-partnered pembrolizumab product also set to provide an early test of the US agency’s new streamlined approach to biosimilar evaluation.
Generics Bulletin - October 13, 2026

Teva Seeks To Shake Up Schizophrenia Market With Long-Acting Injectable Olanzapine Approval
With FDA approval now in hand, Teva is preparing to launch within a matter of weeks its Weltruza long-acting injectable olanzapine, seeking to build on the success of its Uzedy risperidone counterpart.
Generics Bulletin - October 13, 2026

Spain’s Biotech Boom Tests Europe’s Capital Gap
Spain's biotech sector raised a record €408m in 2025, but small rounds and thin talent pools persist. Investors, pharma dealmakers and industry leaders disagree on whether to emulate Boston or forge a distinct, pan-European model.
In Vivo - October 13, 2026

Strategic Intent: Celebrity Marketing In The Age Of Promo Crackdown
Arcutis CEO Frank Watanabe explains the thinking behind the company’s celebrity partnerships, including the newly announced deal with Simone Biles, and how a small biotech built a commercial strategy for Zoryve against 70 years of topical steroid dominance.
In Vivo - October 13, 2026

Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: China’s competitive threat; M&As cool off in Q3; new pneumococcal vaccine contender; strategy for Spanish biotechs; and Shionogi’s $2bn acquisition.
Scrip - October 13, 2026

Galleri Panel Aftermath: What Investors And Rivals See Next For MCEDs As FDA Decision Looms
An FDA panel voted in favor of Galleri on safety, effectiveness and benefit-risk, but a split effectiveness vote and advice to avoid “early” framing leave claims, rivals’ strategies and Medicare coverage unsettled, an investor and two rivals told Medtech Insight.
Medtech Insight - October 13, 2026

Chinese AI-Driven Biotechs Keep Up Fundraising Momentum
LigIT.AI and Nutshell Therapeutics raise new funding for the development of oral cyclic peptides and allosteric drugs, respectively, while multiple other Chinese firms also close new financing rounds.
Scrip - October 13, 2026

DEA Acts On HHS Recommendation To Allow More Room For Risky Derivatives In Kratom Products
DEA changes notice of intent to make 7-OH and MGPI Schedule I controlled substances when either one alone, or combined, exceeds 1mg per gram in solid products or 1mg per milliliter in liquids, or when the ratio of mitragynine to 7-OH, MGPI, or their combined amount is less than 100 to 1.
HBW Insight - October 13, 2026

‘Biggest Beauty Blindspot’: Non-Profit Pushes Lip Product Safety Framework
A new nonprofit aims to modernize global safety standards for lip products, citing outdated models and changes in how consumers are utilizing the products.
HBW Insight - October 13, 2026